Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760837 | 1.00 | ATM (0.57) | ATMALDH1A1LDHAMAPK1POLB | |
| SCHEMBL2249864 | 0.83 | ATM (0.54) | ATMALDH1A1LDHAMAPK1POLB | |
| SCHEMBL30219090 | 0.82 | ATM (0.53) | ATMALDH1A1LDHAMAPK1POLB | |
| SCHEMBL29213279 | 0.82 | ATM (0.53) | ATMALDH1A1LDHAMAPK1POLB | |
| SCHEMBL29213273 | 0.82 | ATM (0.53) | ATMALDH1A1LDHAMAPK1POLB | |
| SCHEMBL1760907 | 0.81 | LDHA (0.53) | ATMALDH1A1LDHAKMT2AMEN1 | |
| SCHEMBL1927881 | 0.81 | LDHA (0.53) | ATMALDH1A1LDHAKMT2AMEN1 | |
| SCHEMBL1760820 | 0.81 | LDHA (0.53) | ATMALDH1A1LDHAKMT2AMEN1 | |
| SCHEMBL11145580 | 0.78 | ACE (0.47) | POLBKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL29538555 | 0.78 | MC4R (0.54) | ATMALDH1A1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947850-B2 | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1996192-A2 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | Inspire Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080287683-A1 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | DECAMP JONATHAN B | 2008-11-20 | — | — | US | disclosed |
| US-7414137-B2 | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007109786-A2 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225504-A1 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | INSPIRE PHARMACEUTICALS, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225504-A1 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | ACTR2, ACTR5, ACTR3 | ATM 3049/4885ALDH1A1 4259/4885LDHA 4800/4885 |
| US-20080287683-A1 | PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES | ACTR2, ACTR5, ACTR3 | ATM 3049/4885ALDH1A1 4259/4885LDHA 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.